Relationship between the combination of platelet count and neutrophil-lymphocyte ratio and prognosis of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: A retrospective cohort study

Saeko Kashimura ¹, Miki Sato ¹, Takahito Inagaki ^2,3

⁰Division of Pharmacotherapeutics, Department of Clinical Pharmacy, Showa University School of Pharmacy, Tokyo, Japan.

Thoracic Cancer +

|

August 28, 2024

View abstract on PubMed

Summary

The combination of platelet count and neutrophil-lymphocyte ratio (COP-NLR) is a key prognostic factor for advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitor (ICI) therapy. A lower COP-NLR score indicates a better treatment response.

Area Of Science

Oncology
Immunotherapy
Biomarkers

Background

Prognostic value of COP-NLR in advanced NSCLC with ICI combination therapy is unclear.
Need to identify patients benefiting from ICI combination therapy for NSCLC.
Evaluating COP-NLR in relation to treatment response is crucial.

Purpose Of The Study

Investigate prognostic factors, including COP-NLR, for advanced NSCLC patients receiving ICI combination therapy.
Identify patients likely to benefit from this treatment.
Assess the relationship between COP-NLR during therapy and treatment response.

Main Methods

Retrospective cohort study of 88 NSCLC patients.
Primary outcome: overall survival (OS).
Cox proportional hazards model for prognostic factors; chi-square test for COP-NLR and response.

Main Results

Median OS was 15.7 months.
Poor prognostic factors identified: ECOG PS 2, ≥2 distant metastatic sites, baseline COP-NLR 1 or 2.
Higher response rates (CR/PR) observed with a 3-week COP-NLR of 0 compared to scores of 1 or 2.

Conclusions

Baseline COP-NLR, ECOG PS, and metastatic sites are prognostic factors in NSCLC patients on ICI combination therapy.
A lower 3-week COP-NLR score correlates with a positive treatment response.

Keywords:

combination of platelet count and neutrophil‐lymphocyte ratio immune checkpoint inhibitors non‐small cell lung cancer prognosis treatment outcome